Cancer Center

Phone Numbers

General Cancers Nurse Navigator
(803) 791-2289
(803) 791-2617
Support Group Network
(803) 791-2800
Breast Cancer Nurse Navigator
(803) 791-2521
(800) 635-0858
Women's Imaging
(803) 791-2486
Medical Social Services
(803) 791-2430
Lexington Radiation Oncology
(803) 791-2575
Radiology Department
(803) 791-2460
Medical Day Infusion Center
(803) 791-2287
Manager for Cancer Programs
(803) 936-8050

Clinical Trials

Locally Available Clinical Trials

Clinical trials are important medical research studies. People volunteer for these studies to test new drugs, treatment options or combinations of therapy. By participating in a clinical trial, patients can access the latest available treatment options. Each has unique criteria. The following clinical trials re now underway at Lexington Medical Center.

GI 157 Phase 2

Status: OPEN-IIT
Research Hotline: 
803-461-3708

Details: A phase I study of c-met inhibitor ARQ197 in combination with FOLFOX for the treatment of patients with advanced solid tumors with a phase II portion for patients with previously untreated metastatic gastroesophageal cancer

Posted By: Dr. Baldwin, Principal Investigator

Posted Date: July 1, 2013

LUN 239

Status: OPEN-IST
Research Hotline: 
803-461-3708

Details: A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Posted By: Dr. El Geneidy, Principal Investigator

Posted Date: July 1, 2013

GU 92

Status: OPEN-IST
Research Hotline: 
803-461-3708

Details: Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer

Posted By: Dr. Sommers, Principal Investigator

Posted Date: July 1, 2013

CLL 27

Status: OPEN-IST
Research Hotline: 
513-751-2273  ext. 27119

Details: A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Posted By: Dr. Essell, Principal Investigator

Posted Date: July 1, 2013

GI 168

Status: OPEN-IIT
Research Hotline: 
803-461-3708

Details: A Phase II Study of 5-Fluorouracil, Aflibercept, and Radiation in the Preoperative or Adjuvant Treatment of Patients with Stage II / III Rectal Cancer

Posted By: Dr. El Geneidy, Principal Investigator

Posted Date: July 1, 2013

LUN 234

Status: OPEN-IST
Research Hotline: 
803-461-3708

Details: An Open-Label Randomized Phase III Trial of BMS-936558 Versus Docetaxel in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: July 1, 2013

Location: Lexington Oncology

LUN 226

Status: OPEN-IST
Research Hotline: 
803-461-3708

Details: An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Metastatic Non-small Cell Lung Cancer (NSCLC)

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: July 1, 2013

Location: Lexington Oncology

GI 179

Status: OPEN-IST
Research Hotline: 
803-461-3708

Details: A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: July 1, 2013

Location: Lexington Oncology

MPN 03

Status: ON HOLD-IST
Research Hotline: 
803-461-3708

Details: An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera-Myelofibrosis (PPVMF) or Post Essential Thrombocythemia-Myelofibrosis (PET-MF)

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: July 1, 2013

Location: Lexington Oncology

GI 171

Status: OPEN-IST
Research Hotline: 
803-461-3708

Details: A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5 Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab,Oxaliplatin, and a Fluoropyrimidine

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: July 1, 2013

Location: Lexington Oncology

BRE 208

Status: OPEN-IST
Research Hotline: 
803-461-3708

Details: An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER 2+) Metastatic Breast Cancer (SyStHERS)

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: July 1, 2013

Location: Lexington Oncology

GI 162

Status: OPEN-IST
Research Hotline: 
803-461-3708

Details: Randomized Double-Blind, Placebo Controlled, Phase II Study of FOLFOX/ Bevacizumab with or without Met MAb as First-Line Treatment for Patients with Metastatic Colorectal Cancer

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: December 31, 2012

Location: Lexington Oncology

SUP 01

Status: OPEN-IST 
Research Hotline: 

Details: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MEC).

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: December 31, 2012

BRE 197

Status: OPEN– IST
Research Hotline:
803-461-3708

Details: A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer.

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: William M. Butler, MD, FACP, Principal Investigator

Posted Date: December 31, 2012

BRE 186

Research Hotline: 803-461-3708

Details: Phase 2 Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy. 

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: December 31, 2012

BRE 193

Status: OPEN-IST
Research Hotline:
803-461-3708

Details: A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus.  

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Anne S. Hutchison, MD, Principal Investigator

Posted Date: December 31, 2012

RTOG 1005

Details: A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer 

Posted By: Quillin Davis, MD, Principal Investigator

Posted Date: August 18, 2011

Location: LMC Radiation Oncology

Iressa Clinical Access Program

Details: An Open Label, Multi-Center IRESSA, Clinical Access Program of Gefitinib 250 mg (Iressa) for the continued treatment of patients in the United States who are currently benefiting or have benefited from Gefitinib treatment

Posted By: Asheesh Lal, MD, Principal Investigator

Posted Date: June 9, 2011

Location: Lexington Oncology

P10-3

Details: A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer - Steve Madden, MD, principal investigator.

Posted By: Steve Madden, MD, Principal Investigator

Posted Date: November 2, 2011

Location: Lexington Oncology

LYM 67

Status: OPEN - IST
Research Hotline: 803-461-3708

Details: An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non- Germinal Center B-Cell like Diffuse Large B-Cell Lymphoma

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: August 1, 2011

LYM 74

Status: OPEN - IST
Research Hotline: 803-461-3708

Details: A Phase III, Multicenter, Randomized Trial Comparing the Efficacy of GA101 in Combination with CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL). 

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: August 1, 2011

OBS 03

Status: OPEN - IIT
Research Hotline: 803-461-3708

Details: Connect CLL Registry Protocol

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: August 1, 2011

MM 23

Status: ON HOLD - IIT
Research Hotline: 803-461-3708

Details: Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of patients with Multiple Myeloma Who are not Candidates for High Dose Chemotherapy.

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: August 1, 2011

S1007

Status: OPEN
Contact: (803) 794-7511

Details: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.

Posted By: Steve Madden, MD, Principal Investigator

Posted Date: June 28, 2011

Location: Lexington Oncology

Southeast Biorepository System Protocol (Two Studies)

About the Southeast Biorepository System

This is the overarching protocol for our tissue banking program. Once this protocol was approved by LMC's IRB, we were able to begin collecting and banking tissue to be held in reserve for future research studies.

After approximately one year of collections, LMC was able to support the opening of its first tissue banking related study.


Approved Studies:

Title: Approved Study #1: Factors Associated with
Anti-tumor Immunity in Cancer Patients
Approval Date: January 30, 2008
Principal Investigator: Juhua Zhou, Ph.D.

Details: The aim of this study is to better understand how cancer develops and how the body's immune system works to defeat tumor cells.

The results of this study will provide valuable clues in improving the efficacy of adoptive cell transfer therapy (ACT) (isolating antigen-specific cells from the patient, expanding and activating these cells, and then re-administering the "boosted" cells back to the patient) and cancer vaccination therapy in cancer patients. )

Title: Approved Study #2: Genetic Predictors of Colon Cancer Recurrence
Approval Date: July 29, 2009
Principal Investigator: Phillip Buckhaults, Ph.D.

Details: The purpose of this study is to determine if genetic markers of positive lymph node involvement can predict recurrence among node-negative colon cancer patients.


Completed Studies:

Title: Examination of KLF4 Expression in Kidney and
Breast Cancers
Principal Investigator: Walden Ai, Ph.D.
Details: KLF4 is a protein involved in cell proliferation. The over expression of KLF4 has been reported in breast cancer and may play a role in cancer development.

The aim of this study is to examine KLF4 expression in kidney and breast cancers and to further examine the over expression of KLF4 may play in the development of these cancers.

Posted By: LMC IRB

Posted Date: December 14, 2010

Location: Lexington Medical Center

LUN 222

Status: OPEN - IST
Research Hotline: 803-461-3708

Details: A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Metmab In Combination With Tarceva (Erlotinib), In Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC), Who Have Received Standard Chemotherapy For Advanced Or Metastatic Disease.

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: November 30, 2010

LUN 225

Status: OPEN - IST
Research Hotline: 803-461-3708

Details: A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with Advanced Solid Tumors including Extensive Stage Small Cell Lung Cancer.

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: December 31, 2012

LUN 196

Status: OPEN - TIER II
Research Hotline: 803-461-3708

Details: TOPPS (Trial Of Poor Performance Status patients): Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients with Stage III/IV Non-Small Cell Lung Cancer and ECOG Performance Status 2.

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: November 30, 2010

LUN 186

Status: OPEN - IIT
Research Hotline: 803-461-3708

Details: Phase II Trial of Preoperative Pemetrexed and Carboplatin in Patients with Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer.

This clinical trial is being offered at the following location: South Carolina Oncology Associates

Posted By: Fred J. Kudrik, MD, Principal Investigator

Posted Date: November 29, 2010